Human ILT7/CD85g APC-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: LILRA4/CD85g/ILT7

ILT7, also known as LILRA4 and CD85g, is a 499 amino acid (aa) type I transmembrane glycoprotein that contains four Ig-like domains in its extracellular region. ILT7 is selectively expressed on plasmacytoid dendritic cells (pDC). It binds to BST2/CD317 on bone marrow stromal cells and associates with the gamma subunit of Fc epsilon RI. This receptor complex transmits signals that inhibit the TLR-induced production of type I interferon. The ILT7-mediated interactions between pDC and tumor cells similarly inhibit the production of proinflammatory cytokines and contribute to reduced anti-tumor immune responses. Alternate splicing of human ILT7 generates an isoform that lacks the N-terminal 43 aa of the extracellular domain.

Product Datasheets

Related Research Areas

• Airway Inflammation and Remodeling
• Angiopoietins, Angiopoietin-like Proteins, and Receptors
• Co-stimulatory and Co-inhibitory Molecules
• Dendritic Cell Activation
• Eosinophils
• ITIM/ITAM Immunoreceptors and Related Molecules
• Monocyte Markers
• T Cell Antigen Recognition